From mRNA combination vaccines to targeted therapies for pediatric tumors: the EMA drives a new balance between innovation, clinical benefit, and social responsibility. By Ehab Soltan HoyLunes – From the halls of its Amsterdam headquarters, the European Medicines Agency (EMA) is doing more than just validating molecules; it is redefining the operational framework of European healthcare for the coming decade.…
Read MoreEurope, Vaccines, and Childhood Cancer: Medicine’s New Social Contract According to the EMA
